Promising new treatments are on the horizon, according to Jeffrey Glassberg, MD, MA, Assistant Professor of Emergency Medicine, Hematology and Medical Oncology and Associate Director of The Mount Sinai Comprehensive Sickle Cell Program at the Icahn School of Medicine at Mount Sinai.
